Normunity
Oncology Therapeutics · Biotechnology
$223.4Mtotal raised · 4 rounds on record
$75Mlatest round · Series B · Jan 2025 · 21 mo ago
2backers · Canaan Partners, Taiho Ventures
16team · US Form 5500 (plan participants) · Dec 2025 · +23% in a year
Overview
We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
Key facts
These are the key facts about Normunity on Alion as of Nov 13, 2026. Normunity is headquartered in Westport, United States. It was founded in 2020. It has raised $223.4M in 4 funding rounds. The latest round is Series B of $75M, announced in 2025.
- Headquarters
- Westport, United StatesAlion company profile, updated Sep 28, 2026
- Founded
- 2020Alion company profile, updated Sep 28, 2026
- Employees
- 200+Alion company profile, an estimated range
- Total raised
- $223.4MSum of 4 equity rounds Alion knows
- Latest round
- Series B · $75M · Jan 12, 2025Press report · streetinsider.com
Official records
Funding and backers
Total raised
$223.4M
4 rounds on record
Latest round
$75M
Series B · Jan 2025 · 21 mo ago
Team
16
US Form 5500 (plan participants) · Dec 2025 · +23% in a year
Backers
2
Canaan Partners, Taiho Ventures
The money's age
Due for its next round
21 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 12, 2025
Raised a round Series B $75M
Jul 10, 2023
Board appointment Normunity appoints industry leader Debanjan Ray to Board of Directors · businesswire.com
Jan 18, 2023
New executive Normunity Appoints Olga Granaturova as Chief Operating Officer and Chief Business Officer · businesswire.com
Oct 25, 2022
Raised a round Series A $65M
Jan 11, 2022
Raised a round Venture round $45.9M · SEC Form D
2020
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Jan 2025 | $75M | — | streetinsider.com |
| Venture round | Jan 2025 | $37.5M | — | SEC Form D |
| Series A | Oct 2022 | $65M | — | normunity.com |
| Venture round | Jan 2022 | $45.9M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Normunity Holding Company, LLC | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Rachel HumphreyExecutive Officer, DirectorSEC Form D
Scott PhillipsExecutive OfficerSEC Form D
Darlene Deptula-HicksExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Frontiermeds
backs Alterome
Similar startupsby what they do, their industry and backers
Leading the Way in Humoral Immuno-Oncology. At Navrogen, our team of experts is striving to provide innovative solutions to overcome…
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and…
Imcheck Therapeutics : Opening new spaces in Immuno-Oncology.
IDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells…
Lever Bio aims to translate groundbreaking discoveries in immuno-oncology into next-generation cancer immunotherapies.
Cairn Therapeutics: Targeting the Cancer, just the cancer. Making cancer treatment simpler and safer with CT-262.
People
Rachel Humphrey
Executive Officer, Director
Scott Phillips
Executive Officer
Darlene Deptula-Hicks
Executive Officer
Timothy Shannon
Director
Yunxia Yang
Director
James Trenkle
Director
Sakae Asanuma
Director
David Parry
Director
Sara Nayeem
Director
Marie-Claire Peakman
Director
Paulina Hill
Director
Debanian Ray
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Taiho VenturesVia a fund
Canaan PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Normunity to Participate in the TD Cowen 46ᵗʰAnnual Health Care Conference
BOSTON and NEW HAVEN, Conn., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Normunity, a clinical stage biotechnology company pioneering precision biologics, today announced that management will participate in the TD Cowen 46thAnnual Health Care Conference, taking pla
Read more
Report
Normunity to Participate in the TD Cowen 46th Annual Health Care Conference
Boston, Mass., and New Haven, Conn. - February 4, 2026 - Normunity, a clinical stage biotechnology company pioneering precision biologics, today announced that management will participate in the TD Cowen 46th Annual Health Care Conference, taking place Ma
Read more
Report
Normunity announces first patient dosed in Phase 1 clinical study of NRM 823, a T Cell Engager against a novel tumor-specific target, in patients with solid tumors
Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastatic refractory solid tumors NRM-823 is a T cell engager against an immuno-active novel target that is h
Read more
Report
Normunity announces first patient dosed in Phase 1 clinical study of NRM-823, a T Cell Engager against a novel tumor-specific target, in patients with solid tumors
Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastatic refractory solid tumors NRM-823 is a T cell engager against an immuno-active novel target that is h
Read more
Report
Normunity raises $75m to advance solid tumour targeting T-cell engagers
US-based biotech Normunity plans to initiate a Phase I clinical trial of NRM-823 in the second half of 2025.
Read more
Report
Normunity closes $75 million Series B financing to advance lead drug program into the clinic and broaden pipeline of novel anti-cancer therapies targeting untapped drug mechanisms
Read more
Report
Normunity Closes $75 Million Series B Financing to Advance Lead Drug Program Into the Clinic and Broaden Pipeline of Novel Anti-Cancer Therapies Targeting Untapped Drug Mechanisms
Read more
Report
Report
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Westport
United States
HQ
New Haven
United States
Engineering / R&D
Normunity Office and labs
101 College Street, New Haven, CT 06510
Boston
United States
Normunity Corporate Office
1 Beacon St., 15th Floor, Boston, MA 02108
How to cite this page
Alion, "Normunity: key facts", as of Nov 13, 2026. https://alion.io/company/normunity
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0